Core Insights - On October 23, 2025, Alibaba-W (09988), Pop Mart (09992), and SMIC (00981) were the top three companies by trading volume in the southbound trading of the Stock Connect, with trading amounts of 4.975 billion, 4.666 billion, and 3.522 billion respectively [1][2] - In the southbound trading of the Shenzhen-Hong Kong Stock Connect, Alibaba-W (09988), SMIC (00981), and Pop Mart (09992) also ranked as the top three, with trading amounts of 3.277 billion, 2.585 billion, and 2.360 billion respectively [1][2] Southbound Trading Highlights - **Top Active Companies in Southbound Trading (Hong Kong Stock Connect)** - Alibaba-W (09988): 4.975 billion, net inflow of 268 million - Pop Mart (09992): 4.666 billion, net inflow of 538 million - SMIC (00981): 3.522 billion, net inflow of 463 million - Meituan-W (03690): 2.699 billion, net inflow of 37.728 million - Huahong Semiconductor (01347): 2.359 billion, net outflow of 356 million - CNOOC (00883): 1.987 billion, net inflow of 529 million - Tencent Holdings (00700): 1.804 billion, net inflow of 102 million - Genscript Biotech (02367): 1.429 billion, net inflow of 279 million - Shandong Hi-Speed (00412): 1.359 billion, net inflow of 67.296 million - Xiaomi Group-W (01810): 1.350 billion, net inflow of 183 million [2] - **Top Active Companies in Southbound Trading (Shenzhen-Hong Kong Stock Connect)** - Alibaba-W (09988): 3.277 billion, net outflow of 115 million - SMIC (00981): 2.585 billion, net outflow of 37.824 million - Pop Mart (09992): 2.360 billion, net inflow of 255 million - Huahong Semiconductor (01347): 1.624 billion, net outflow of 659 million - Meituan-W (03690): 1.534 billion, net inflow of 487 million - Tencent Holdings (00700): 1.217 billion, net inflow of 163 million - CNOOC (00883): 1.167 billion, net inflow of 451 million - Xiaomi Group-W (01810): 1.054 billion, net outflow of 240 million - Genscript Biotech (02367): 826 million, net inflow of 80.645 million - Innovent Biologics (01801): 797 million, net outflow of 14 million [2]

Group 1 - Southbound funds net bought Hong Kong stocks worth 5.345 billion HKD today [1] - The top net purchases included China National Offshore Oil Corporation (CNOOC) at 979 million HKD, Pop Mart at 793 million HKD, and Meituan-W at 524 million HKD [1] - Southbound funds have net bought Pop Mart for three consecutive days, totaling 2.15428 billion HKD, and have also net bought SMIC for three consecutive days, totaling 1.19602 billion HKD [1] Group 2 - Alibaba-W saw a net purchase of 268 million HKD despite a 1.7% decline [3] - CNOOC experienced a 2.2% increase with a net purchase of 529 million HKD [3] - Tencent Holdings had a net purchase of 163 million HKD with a 1.5% increase [3]

Group 1 - Southbound funds recorded a net purchase of 5.345 billion HKD today [1] - The top three net purchases were China National Offshore Oil Corporation (CNOOC) with 980 million HKD, Pop Mart with 793 million HKD, and Meituan-W with 524 million HKD [1] - In terms of net sales, Hua Hong Semiconductor faced a net sell of 1.014 billion HKD, followed by Innovent Biologics with 140 million HKD, and Xiaomi Group-W with 57 million HKD [1]

Core Insights - The Hong Kong stock market saw a net inflow of 53.45 billion HKD from Northbound trading on October 23, with the Shanghai Stock Connect contributing 47.7 billion HKD and the Shenzhen Stock Connect contributing 5.75 billion HKD [1] Group 1: Stock Performance - The most bought stocks included CNOOC (00883), Pop Mart (09992), and Meituan-W (03690) [1] - The most sold stocks included Hua Hong Semiconductor (01347), Innovent Biologics (01801), and Xiaomi Group-W (01810) [1] Group 2: Individual Stock Details - CNOOC (00883) received a net buy of 9.79 billion HKD, driven by rising international oil prices due to sanctions on Russian oil companies [5] - Pop Mart (09992) saw a net buy of 7.93 billion HKD, with a reported sales growth of 245% to 250% in Q3, significantly exceeding Morgan Stanley's forecast [5] - Meituan-W (03690) had a net buy of 5.24 billion HKD, with strategic leadership changes indicating a focus on international expansion [6] - Semiconductor stocks showed divergence, with SMIC (00981) receiving a net buy of 4.25 billion HKD, while Hua Hong Semiconductor (01347) faced a net sell of 10.14 billion HKD due to concerns over its business sustainability [6] - Zai Lab (02367) received a net buy of 3.59 billion HKD following the approval of a new medical device [7] - Tencent (00700) and Alibaba-W (09988) had net buys of 2.65 billion HKD and 1.53 billion HKD, respectively, while Innovent Biologics (01801) and Xiaomi Group-W (01810) faced net sells of 1.4 billion HKD and 573 million HKD [7]

Core Insights - The Hong Kong stock market saw a net inflow of 53.45 billion HKD from northbound trading on October 23, with the Shanghai-Hong Kong Stock Connect contributing 47.7 billion HKD and the Shenzhen-Hong Kong Stock Connect contributing 5.75 billion HKD [1] Group 1: Stock Performance - The most bought stocks included CNOOC (00883), Pop Mart (09992), and Meituan-W (03690) [1] - The most sold stocks included Hua Hong Semiconductor (01347), Innovent Biologics (01801), and Xiaomi Group-W (01810) [1] - CNOOC received a net buy of 9.79 billion HKD, driven by rising international oil prices due to sanctions on Russian oil companies [4] - Pop Mart saw a net buy of 7.93 billion HKD, with a reported sales growth of 245% to 250% in Q3, significantly exceeding Morgan Stanley's forecast [5] - Meituan-W received a net buy of 5.24 billion HKD, with strategic leadership changes indicating a focus on international expansion [5] Group 2: Sector Insights - Semiconductor stocks showed divergence, with SMIC (00981) receiving a net buy of 4.25 billion HKD, while Hua Hong Semiconductor faced a net sell of 10.14 billion HKD [5][6] - The demand for domestic advanced wafer foundry services is expected to rise due to the growth of AI applications and supportive policies [6] - Giant Biologics (02367) received a net buy of 3.59 billion HKD following the approval of a new medical device by the National Medical Products Administration [6]

Core Insights - Sinda Biopharma (01801) has entered into a global strategic collaboration with Takeda Pharmaceutical, which includes two late-stage therapies IBI363 (PD-1/IL-2α-bias) and IBI343 (CLDN18.2 ADC), as well as an early-stage project IBI3001 (EGFR/B7H3 ADC) [1][2] - The collaboration will provide Sinda Biopharma with an upfront payment of $1.2 billion, including a strategic equity investment of $100 million, with potential milestone payments reaching up to $10.2 billion and potential sales sharing [1][2] - IBI363 is viewed as a next-generation cornerstone therapy for tumors, with a significant market potential, targeting a global immune-oncology (IO) responder population of approximately 1.5 million, corresponding to a $50 billion hot tumor market [1] Group 1 - IBI363 has accumulated clinical data from over 1,200 patients, with plans to advance its global development in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC), including first-line indications [2] - The first global Phase 3 clinical study (MarsLight-11) for IBI363 has received FDA approval, focusing on IO-resistant squamous NSCLC patients, comparing the efficacy and safety of IBI363 at a 3 mg/kg dose against docetaxel [2] - The collaboration model will help Sinda Biopharma build experience in global clinical and commercialization teams, leveraging its development efficiency in China and Takeda's international capabilities [2] Group 2 - Takeda invests approximately $5 billion annually in R&D and has a clinical team of 4,500, possessing extensive experience in oncology and immunotherapy [2] - This partnership is expected to enhance Sinda Biopharma's global footprint, gradually establishing R&D and commercialization capabilities in key international markets, maximizing long-term sustainable value [2]

Core Viewpoint - Cinda Biologics (01801) has entered a global strategic partnership with Takeda Pharmaceutical to co-develop the next-generation IO cornerstone therapy IBI363, along with licensing agreements for IBI343 and IBI3001 [1] Group 1: Financial Impact - According to the report by Credit Lyonnais, the sales and net profit forecasts for Cinda Biologics for the fiscal year 2026 have been raised by 48.5% and 172% respectively, while the net profit forecast for 2027 has been increased by 1.5% [1] - The target price for Cinda Biologics has been adjusted from HKD 111.4 to HKD 120.1, maintaining an "outperform" rating [1] Group 2: Product Development and Market Strategy - The collaboration is viewed positively for Cinda's global expansion and product development, particularly in advancing the core project IBI363 [1] - IBI363 received FDA approval in August this year to initiate a Phase III clinical trial for the treatment of squamous non-small cell lung cancer [1] - The plan for joint commercialization of IBI363 in the U.S. is expected to unlock market value, leveraging Takeda's strong commercial rights and experience in the U.S. market [1]

Core Viewpoint - Citibank reports that Innovent Biologics (01801) has entered into a global strategic collaboration with Takeda Pharmaceutical to jointly develop the next-generation IO cornerstone therapy IBI363, along with licensing agreements for IBI343 and IBI3001 [1] Financial Impact - Following this collaboration, Citibank has raised its sales and net profit forecasts for Innovent Biologics for the fiscal year 2026 by 48.5% and 172% respectively, and the net profit forecast for 2027 has been increased by 1.5% [1] - The target price for Innovent Biologics has been adjusted from HKD 111.4 to HKD 120.1, while maintaining an "Outperform" rating [1] Strategic Significance - The collaboration is viewed positively for Innovent's global expansion and product development, particularly in advancing the core project IBI363 [1] - IBI363 received FDA approval in August this year to initiate a Phase III clinical trial for the treatment of squamous non-small cell lung cancer [1] - The plan for joint commercialization of IBI363 in the U.S. is expected to unlock market value, with Takeda's strong U.S. commercial rights and extensive experience in the market being advantageous [1]

Core Insights - The report highlights the performance of the Changcheng Pharmaceutical Industry Selected Mixed A Fund, which has shown significant growth in equity scale, particularly in the technology sector, despite recent market adjustments [1][3]. Performance Analysis - As of October 22, 2025, the fund's unit net value is 1.7983, with a cumulative return of 79.83% since its establishment on October 22, 2024, and a year-to-date increase of 88.34% [1][3]. - The fund has experienced a notable decline of -8.81% over the past month and -14.29% over the last three months, indicating challenges faced by the pharmaceutical sector, especially in the innovative drug field during the third quarter [3][4]. Portfolio Composition - The top ten holdings of the fund have a combined market value of 1.313 billion, heavily concentrated in the innovative drug sector, which differs from the asset allocation logic of technology funds [4]. - The top three holdings include Innovent Biologics, 3SBio, and Hotgen Biotech, with a clear focus on biotechnology and innovative pharmaceutical companies [5]. Investment Strategy - The fund manager, Liang Furui, noted that the A/H market saw multiple sectors rise, primarily driven by technology and precious metals, with an average daily trading volume in the A-share market exceeding 2 trillion [5]. - Despite the strong performance of technology sectors, innovative drugs have entered a correction phase due to significant gains in the first half of the year and negative impacts from TMT-focused capital outflows [5][6]. - Liang Furui emphasized that many innovative drug stocks are now highly cost-effective, suggesting a shift towards selecting individual stocks with genuine competitive advantages as the sector moves into an "individual alpha phase" [6]. Future Outlook - The focus will be on increasing the weight of stocks with global competitiveness and scarcity in core pipelines, balancing long-term potential, drug certainty, and international market viability [6].

Core Viewpoint - Bank of America Securities has raised the revenue forecasts for Innovent Biologics (01801) for 2026 and 2027 by 50% and 3% respectively, while also increasing the earnings per share estimates by 513% and 9% for the same years, and has adjusted the target price from HKD 106.9 to HKD 113, maintaining a "Buy" rating [1] Group 1 - Innovent Biologics has entered into a strategic collaboration with Takeda Pharmaceutical, involving three pipeline projects: IBI-363, IBI-343, and IBI-3001, with an upfront payment of USD 1.2 billion, including a USD 100 million equity investment from Takeda [1] - For IBI-363, both companies will co-develop the product globally and share the commercialization costs in the U.S. at a ratio of 40% for Innovent and 60% for Takeda, while Innovent retains the development rights in China and is entitled to royalties from sales outside of China and the U.S. [1] - The significant transaction underscores Innovent Biologics' research and development capabilities and asset value, marking an important step towards becoming a multinational pharmaceutical company [1]